Phase 2 Licensing Deal Benchmarks

Median Upfront

$258M

Range: $144M - $365M

Total Deal Value

$1.6B

Range: $1.1B - $2.2B

Royalty Rate

11.8% - 19.3%

Tiered up to 23.3%

Dev Milestones

$345M

Range: $230M - $461M

Model Your Deal

Market Analysis

Phase 2 represents the most active deal-making stage in biopharma licensing, where proof-of-concept data transforms asset valuations. Median total deal values at Phase 2 reach $1.6B, with upfront payments between $144M and $365M. This stage offers the optimal balance of de-risking and upside potential for both licensors and licensees.

Phase 2 deal structures balance upfront and milestone payments effectively. The 16/84 upfront/milestone split reflects moderate clinical risk. Development milestones average $345M, while regulatory milestones of $552M and commercial milestones of $483M reward successful progression to market.

Royalty rates at Phase 2 range from 11.8% to 19.3%, the mid-range of industry norms. Assets with pivotal-ready Phase 2 data (clear efficacy signal, manageable safety, well-defined patient population) command premium terms approaching Phase 3 valuations, while assets with mixed or preliminary data trade at discounts.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the average total deal value for Phase 2 licensing?

Phase 2 licensing deals average $1.6B total deal value, ranging from $1.1B to $2.2B. This reflects the proof-of-concept de-risking that occurs at this stage.

How do Phase 2 deal terms compare to Phase 1 and Phase 3?

Phase 2 deals represent a significant step-up from Phase 1, with 50-100% higher total deal values. Phase 3 deals command approximately 40-80% more than Phase 2, reflecting the additional regulatory de-risking. Phase 2 is considered the optimal licensing window for many licensors.

What data quality factors affect Phase 2 deal valuations?

Key factors include statistical rigor of efficacy data, durability of response, safety profile relative to competitors, biomarker data supporting patient selection, and clarity of the Phase 3 development path. Pivotal-ready Phase 2 data can drive valuations approaching Phase 3 levels.

Why is Phase 2 considered the optimal licensing window?

Phase 2 offers the best risk-reward balance for licensing. Licensors have demonstrated proof of concept, commanding meaningful upfronts, while licensees can still capture significant value appreciation through Phase 3 completion and commercialization. This window maximizes total deal value relative to remaining development risk.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating

Phase 2 Licensing Deal Benchmarks

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

Preclinical Deal Benchmarks

Phase 3 Deal Benchmarks

ADC Deal Benchmarks

Oncology Deal Overview 2026

Ready to Calculate Your Deal Terms?